STATCenter·
STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.
Read at STAT →
Health · 1 sources covering this
STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/b6878f121f5a5400cda2f5f01cb405cdb1d15324" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley"></iframe>
